ArticleFrontiers in immunology2026
Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive therapy with CD19 chimeric antigen receptor (CAR) T cells is effective against B-cell malignancies; however, T-cell activation rapidly declines, increasing the risk of early leukemia relapses. To augment CD19 CAR T-cell functionality, we interfered with the physiological control of T-cell activation by a CAR that prevents the T cell's inherent CD30-CD30L interaction. Redirected by the bispecific CD30/CD19 CAR, T cells were superior to canonical CD19 CAR T cells in eliminating CD30
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.